Biocon, Bristol-Myers in deal for oral insulin drug

MUMBAI Fri Nov 16, 2012 10:49am IST

Related Topics

Stocks

   

MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.

Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.

Biocon, which has been looking to partner the drug for nearly two years, said it would receive a license fee as well as milestone payments and royalties based on commercial sales of the drug outside India. It will retain the rights to IN-105 in India.

Financial terms of the deal were not available.

Currently, there are no insulin tablets available and patients with diabetes who need insulin -- a naturally occurring protein that controls blood sugar -- must inject it.

Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.

Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.

(Reporting by Aradhana Aravindan; Editing by G.Ram Mohan)

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.

Reuters Showcase

Obama Arrives

Obama Arrives

Bear hug with Modi gets Obama's India trip off to warm start.  Full Article | Pictures 

Japanese Hostages

Japanese Hostages

Japan condemns apparent IS execution, demands hostage release.  Full Article 

Ukraine Crisis

Ukraine Crisis

Pro-Russian rebels attack key port; Ukraine says at least 30 dead.  Full Article 

Australian Open

Australian Open

Nadal, Sharapova charge into quarters as top brass shine.  Full Article 

Row over Film

Row over Film

Group says 'American Sniper' film spurs threats against Muslims.  Full Article 

Movie Review

Movie Review

Dolly ki Doli is a breezy watch, writes Shilpa Jamkhandikar.  Full Article | Related Story 

Akshay Kumar's Latest

Akshay Kumar's Latest

"Baby" is a smartly written, well-acted film  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage